Notice Number: NOT-GM-19-039
Release Date: May 13, 2019
Effective immediately, the National Institute of General Medical Sciences (NIGMS) is transferring its HIV/AIDS portfolio, and all associated funds, to the National Institute of Allergy and Infectious Diseases (NIAID). The transfer will be coordinated by the NIH Office of AIDS Research (OAR) and will improve the scientific coordination, prioritization, and efficiency of utilizing and managing HIV/AIDS dollars traditionally allocated to NIGMS. The HIV/AIDS budget is separate from the general NIGMS appropriation and grants funded by the HIV/AIDS budget must be within defined priority areas established by OAR. Therefore, transferring the HIV/AIDS portfolio and associated funding to NIAID will not adversely affect NIGMS ability to support research in the Institute’s mission areas, nor will it diminish the overall funding available for HIV/AIDS research. NIAID has a strong commitment to basic research related to HIV/AIDS and the expertise necessary to manage grants in this area, including in the structural biology of HIV and related immunology.
Grants related to HIV/AIDS that are not supported by the HIV/AIDS budget, including those funded by the Institutional Development Award (IDeA), Native American Research Centers for Health (NARCH), and the Support of Competitive Research (SCORE) programs will not be affected by this change and will remain at NIGMS.
Effective immediately, HIV/AIDS applications will no longer be accepted by NIGMS for funding consideration. This policy applies to applications submitted to FOAs issued by NIGMS, as well as FOAs in which NIGMS participates along with other NIH Institutes and Centers, including NIH Parent Announcements.
Affected grantees and applicants will be contacted by NIGMS and NIAID staff with further information regarding this transition, including new Program Officer and Grants Management Specialist assignments.
Please direct all inquiries to:
Michael Sakalian, Ph.D.
National Institute of General Medical Sciences (NIGMS)